Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Neuropace Inc (NQ: NPCE )

7.700 +0.050 (+0.65%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 30, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 38,367
Open 7.630
Bid (Size) 5.000 (10)
Ask (Size) 8.910 (1)
Prev. Close 7.650
Today's Range 7.360 - 7.800
52wk Range 4.000 - 18.15
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
NPCE Stock Earnings: NeuroPace Meets EPS, Beats Revenue for Q1 2024
NPCE stock results show that NeuroPace met analyst estimates for earnings per share but beat on revenue for the first quarter of 2024. 
Via InvestorPlace

Performance

YTD
-21.27%
-21.27%
1 Month
+5.19%
+5.19%
3 Month
-40.72%
-40.72%
6 Month
-48.67%
-48.67%
1 Year
+85.54%
+85.54%

More News

Read More
NeuroPace to Report First Quarter 2024 Financial Results on May 8, 2024
From NeuroPace, Inc.
Via GlobeNewswire
The Latest Analyst Ratings For NeuroPace
Via Benzinga
NPCE Stock Earnings: NeuroPace Beats EPS, Beats Revenue for Q4 2023
Via InvestorPlace
Recap: NeuroPace Q4 Earnings
Via Benzinga
Earnings Preview: NeuroPace
Via Benzinga
A Glimpse Into The Expert Outlook On NeuroPace Through 4 Analysts
Via Benzinga
NeuroPace Stock: A Deep Dive Into Analyst Perspectives (6 Ratings)
Via Benzinga
NeuroPace Announces Record Full Year 2023 Revenue of $65.4 Million
From NeuroPace, Inc.
Via GlobeNewswire
Financial Freedom Fighters: 3 Stocks to Liberate Your Portfolio
Via InvestorPlace
Earnings Scheduled For March 5, 2024
Via Benzinga
Breaking Down NeuroPace: 6 Analysts Share Their Views
Via Benzinga
NeuroPace to Present at the 42nd Annual J.P. Morgan Healthcare Conference
From NeuroPace, Inc.
Via GlobeNewswire
NeuroPace to Leverage the Power of its RNS System’s Novel Data Collection, Brain Monitoring and Analysis Capabilities in Groundbreaking Collaboration
From NeuroPace, Inc.
Via GlobeNewswire
Expert Ratings for NeuroPace
Via Benzinga
NeuroPace and the RNS System Showcased at the 77th American Epilepsy Society (AES) Annual Meeting
From NeuroPace, Inc.
Via GlobeNewswire
Expert Ratings for NeuroPace
Via Benzinga
Earnings Scheduled For November 6, 2023
Via Benzinga
NeuroPace to Present at the Piper Sandler 35th Annual Healthcare Conference
From NeuroPace, Inc.
Via GlobeNewswire
Epilepsy-Focused MedTech NeuroPace Has Attractive Entry Point, Competitive Position
Via Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
NeuroPace Reports Third Quarter 2023 Financial Results and Increases Full Year 2023 Revenue Guidance
From NeuroPace, Inc.
Via GlobeNewswire
NeuroPace Announces RNS System Enhancements Designed to Streamline Care
From NeuroPace, Inc.
Via GlobeNewswire
NeuroPace to Report Third Quarter 2023 Financial Results on November 6, 2023
From NeuroPace, Inc.
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.